280 related articles for article (PubMed ID: 29604484)
1. Psychiatric and cognitive adverse events: A pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures.
Andermann E; Biton V; Benbadis SR; Shneker B; Shah AK; Carreño M; Trinka E; Ben-Menachem E; Biraben A; Rocha F; Gama H; Cheng H; Blum D;
Epilepsy Behav; 2018 May; 82():119-127. PubMed ID: 29604484
[TBL] [Abstract][Full Text] [Related]
2. Adjunctive eslicarbazepine acetate: A pooled analysis of three phase III trials.
Biton V; Rogin JB; Krauss G; Abou-Khalil B; Rocha JF; Moreira J; Gama H; Trinka E; Elger CE; Cheng H; Grinnell T; Blum D;
Epilepsy Behav; 2017 Jul; 72():127-134. PubMed ID: 28575761
[TBL] [Abstract][Full Text] [Related]
3. Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: An integrated analysis of three randomized placebo-controlled trials.
Krauss G; Biton V; Harvey JH; Elger C; Trinka E; Soares da Silva P; Gama H; Cheng H; Grinnell T; Blum D
Epilepsy Res; 2018 Jan; 139():1-8. PubMed ID: 29127848
[TBL] [Abstract][Full Text] [Related]
4. Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures.
Abou-Khalil B; Klein P; Shah A; Ryvlin P; Specchio LM; Gama H; Rocha F; Blum D; Grinnell T; Cheng H; Jung J
Epilepsy Res; 2018 Nov; 147():80-86. PubMed ID: 30278294
[TBL] [Abstract][Full Text] [Related]
5. Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures.
Altalib H; Grinnell T; Cantu D; Ikedo F; Vieira M; Zhang Y; Blum D
Epilepsia Open; 2022 Dec; 7(4):616-632. PubMed ID: 35908275
[TBL] [Abstract][Full Text] [Related]
6. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial.
Sperling MR; Abou-Khalil B; Harvey J; Rogin JB; Biraben A; Galimberti CA; Kowacs PA; Hong SB; Cheng H; Blum D; Nunes T; Soares-da-Silva P;
Epilepsia; 2015 Feb; 56(2):244-53. PubMed ID: 25528898
[TBL] [Abstract][Full Text] [Related]
7. Safety and Tolerability of Adjunctive Eslicarbazepine Acetate in Pediatric Patients (Aged 4-17 Years) With Focal Seizures.
Mintz M; Pina-Garza JE; Wolf SM; McGoldrick PE; Józwiak S; Grinnell T; Cantu D; Costa R; Moreira J; Li Y; Blum D
J Child Neurol; 2020 Mar; 35(4):265-273. PubMed ID: 31878820
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures.
Chung S; Sinha SR; Shah A; Stern JM; Cheng H; Jung J; Grinnell T; Blum D
Epilepsy Res; 2019 Jul; 153():59-65. PubMed ID: 30999260
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of the safety and tolerability of eslicarbazepine acetate in older (≥60 years) and younger (18-59 years) adults.
Andermann E; Rosenfeld W; Penovich P; Rogin J; Cendes F; Carreño M; Ramsay RE; Ben-Menachem E; Gama H; Rocha F; Soares-da-Silva P; Tosiello R; Blum D; Grinnell T
Epilepsy Res; 2021 Jan; 169():106478. PubMed ID: 33338829
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials.
Biton V; Gil-Nagel A; Isojarvi J; Doty P; Hebert D; Fountain NB
Epilepsy Behav; 2015 Nov; 52(Pt A):119-27. PubMed ID: 26414341
[TBL] [Abstract][Full Text] [Related]
11. Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies.
Elger C; Koepp M; Trinka E; Villanueva V; Chaves J; Ben-Menachen E; Kowacs PA; Gil-Nagel A; Moreira J; Gama H; Rocha JF; Soares-da-Silva P
CNS Neurosci Ther; 2017 Dec; 23(12):961-972. PubMed ID: 29030894
[TBL] [Abstract][Full Text] [Related]
12. Effects of adjunctive eslicarbazepine acetate on serum lipids in patients with partial-onset seizures: Impact of concomitant statins and enzyme-inducing antiepileptic drugs.
Mintzer S; Wechsler RT; Rogin JB; Gidal BE; Schwab M; Ben-Menachem E; Carreño M; da Silva PS; Moreira J; Li Y; Blum D; Grinnell T
Epilepsy Res; 2018 Mar; 141():83-89. PubMed ID: 29499473
[TBL] [Abstract][Full Text] [Related]
13. Analysis of cutaneous allergic reactions in clinical trials of eslicarbazepine acetate.
Rogin J; Resnick T; Strom L; Ben-Menachem E; Kochen S; Blum D; Gama H; Soares-da-Silva P; Li Y; Grinnell T
Acta Neurol Scand; 2020 May; 141(5):397-404. PubMed ID: 31894578
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of adjunctive eslicarbazepine acetate in adult Asian patients with refractory focal seizures: Post hoc analysis of a phase III trial.
Lee SK; Lee SA; Hong SB; Cho YW; Castilla-Fernández G; Fonseca MM; Moreira J; Gama H; Holenz J
Clin Transl Sci; 2024 May; 17(5):e13802. PubMed ID: 38787305
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: Experience from a multicenter, observational study.
Toledano R; Jovel CE; Jiménez-Huete A; Bayarri PG; Campos D; Gomariz EL; Giráldez BG; García-Morales I; Falip M; Agredano PM; Palao S; Prior MJAA; Pascual MRQ; Navacerrada FJ; González FJL; Ojeda J; Sáez AA; Bermejo PE; Gil-Nagel A
Epilepsy Behav; 2017 Aug; 73():173-179. PubMed ID: 28641170
[TBL] [Abstract][Full Text] [Related]
16. Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience.
Gama H; Vieira M; Costa R; Graça J; Magalhães LM; Soares-da-Silva P
Drug Saf; 2017 Dec; 40(12):1231-1240. PubMed ID: 28752473
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and tolerability of adjunctive eslicarbazepine acetate in children with focal seizures.
Sankar R; Kirkham FJ; Holmes GL; Pina-Garza JE; Wheless J; Gama H; Moreira J; Cantu D; Tosiello R; Blum D; Grinnell T
Epilepsy Behav; 2020 Nov; 112():107458. PubMed ID: 33181890
[TBL] [Abstract][Full Text] [Related]
18. Effects of adjunctive eslicarbazepine acetate on neurocognitive functioning in children with refractory focal-onset seizures.
Jóźwiak S; Veggiotti P; Moreira J; Gama H; Rocha F; Soares-da-Silva P
Epilepsy Behav; 2018 Apr; 81():1-11. PubMed ID: 29454255
[TBL] [Abstract][Full Text] [Related]
19. Serum sodium levels and related treatment-emergent adverse events during eslicarbazepine acetate use in adults with epilepsy.
Wechsler RT; Radtke RA; Smith M; Vossler DG; Strom L; Trinka E; Cheng H; Grinnell T; Blum D; Vieira M; Moreira J; Rocha F
Epilepsia; 2019 Jul; 60(7):1341-1352. PubMed ID: 31260089
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.
Elger C; Halász P; Maia J; Almeida L; Soares-da-Silva P;
Epilepsia; 2009 Mar; 50(3):454-63. PubMed ID: 19243424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
